©The Author(s) 2022.
World J Gastroenterol. Sep 7, 2022; 28(33): 4744-4761
Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4744
Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4744
Table 1 Characteristics of individual colorectal cancer subtypes
| CMS1 | CMS2 | CMS3 | CMS4 |
| (MSI immune) | (Canonical) | (Metabolic) | (Mesenchymal) |
| CIMP high | CIN | CIN, CIMP low | CIN |
| Hypermethylation | |||
| SCNA-low | SCNA-high | SCNA-intermediate | SCNA-high |
| BRAF mutant | KRAS mutant | ||
| Activation of immune cells | WNT, MYC activation | Metabolic deregulation | TGF- activation |
| Worse survival after relapse | Superior survival after relapse | Worse relapse-free and overall survival |
- Citation: Maslankova J, Vecurkovska I, Rabajdova M, Katuchova J, Kicka M, Gayova M, Katuch V. Regulation of transforming growth factor-β signaling as a therapeutic approach to treating colorectal cancer. World J Gastroenterol 2022; 28(33): 4744-4761
- URL: https://www.wjgnet.com/1007-9327/full/v28/i33/4744.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i33.4744